Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis

Company Overview

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Key Stats

• Today's Range: $96.76 to $101.15
• 50-Day Range: $103.11 to $122.23
• 52-Week Range: $67.72 to $129.90
• Volume: 165,795 shs
• Average Volume: 123,626 shs
• Market Capitalization: $1.92 billion
• P/E Ratio: 39.67
• Dividend Yield: N/A
• Price Target: $147.00
• Consensus Rating: Buy

Ligand Pharmaceuticals Stock Analysis - MarketRank™

Ligand Pharmaceuticals scored higher than 87% of companies evaluated by MarketBeat, and ranked 118th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Ligand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Ligand Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 114.45%

Earnings Growth

Earnings for Ligand Pharmaceuticals are expected to grow by 114.45% in the coming year, from $1.73 to $3.71 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ligand Pharmaceuticals is 39.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.03.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ligand Pharmaceuticals is 39.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.18.

Price to Book Value per Share Ratio

Ligand Pharmaceuticals has a P/B Ratio of 2.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.37% of the float of Ligand Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Ligand Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.

Change versus previous month

Short interest in Ligand Pharmaceuticals has recently increased by 22.43%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ligand Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Ligand Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.57

Percentage of Shares Shorted

5.37% of the float of Ligand Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Ligand Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.

Change versus previous month

Short interest in Ligand Pharmaceuticals has recently increased by 22.43%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.13

News Sentiment

Ligand Pharmaceuticals has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Ligand Pharmaceuticals this week, compared to 5 articles on an average week.

MarketBeat Follows

1 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $575,150.00 in company stock.

Percentage Held by Insiders

Only 5.90% of the stock of Ligand Pharmaceuticals is held by insiders.

Percentage Held by Institutions

91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LGND Stock Analysis - Frequently Asked Questions

How have LGND shares performed this year?

Ligand Pharmaceuticals' stock was trading at $107.15 at the start of the year. Since then, LGND stock has decreased by 7.1% and is now trading at $99.57.
View the best growth stocks for 2025 here.

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) posted its earnings results on Tuesday, August, 6th. The biotechnology company reported $1.40 earnings per share for the quarter, topping analysts' consensus estimates of $1.06 by $0.34. The company's revenue was up 57.2% on a year-over-year basis.

Who are Ligand Pharmaceuticals' major shareholders?

Top institutional investors of Ligand Pharmaceuticals include Kings Path Partners LLC (0.03%). Insiders that own company stock include John L Higgins, Matthew W Foehr, Todd C Davis, Matthew E Korenberg, John W Kozarich, John L Lamattina, Stephen L Sabba, Andrew Reardon, Octavio Espinoza and Nancy Ryan Gray.
View institutional ownership trends.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ligand Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 8/06/2024
• Today: 4/04/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LGND
• CIK: 886163
• Web: www.ligand.com
• Phone: (858) 550-7500
• Fax: 858-550-1826
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $147.00
• High Stock Price Target: $160.00
• Low Stock Price Target: $135.00
• Potential Upside/Downside: +48.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.16)
• Trailing P/E Ratio: 39.55
• Forward P/E Ratio: 57.05
• P/E Growth: N/A
• Net Income: $52.15 million
• Net Margins: 29.68%
• Pretax Margin: 38.59%
• Return on Equity: 4.95%
• Return on Assets: 4.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.49
• Quick Ratio: 11.81

Sales & Book Value

• Annual Sales: $167.13 million
• Price / Sales: 11.37
• Cash Flow: $4.05 per share
• Price / Cash Flow: 24.39
• Book Value: $40.39 per share
• Price / Book: 2.44

Miscellaneous

• Outstanding Shares: 19,255,000
• Free Float: 17,780,000
• Market Cap: $1.90 billion
• Optionable: Optionable
• Beta: 1.12